Vaccine Design Book available now
The new book Vaccine Design: Innovative Approaches and Novel Strategies edited by Rino Rappuoli and Fabio Bagnoli has been delivered to our distributors and is available for immediate dispatch read more ...
read more ...
 | Edited by: Rino Rappuoli and Fabio Bagnoli ISBN: 978-1-904455-74-5 Publisher: Caister Academic Press Publication Date: February 2011 Cover: hardback |
Conference Alert: Mechanisms of Vaccination
October 27 - November 1, 2010 Immunological Mechanisms of Vaccination
Seattle, Washington, USA Further information
Immunological Mechanisms of Vaccination will bring together an interdisciplinary group of scientists in immunology, virology, systems biology and vaccinology, to address critical advances in these fields and their implications for vaccinology; The importance of the innate immune system in sensing vaccines and shaping the vaccine immunity; Modulating immune memory to vaccines with innate immunity; Novel approaches to understanding host-pathogen interactions; Deconstructing the mode of action of successful vaccines, vectors adjuvants with innate immunity; Constructing new vaccines and adjuvants with innate immunity; Application of systems biology to predicting vaccine efficacy, and discovering novel immune mechanisms of protection
Suggested reading: Vaccine Design: Innovative Approaches and Novel Strategies
Seattle, Washington, USA Further information
Immunological Mechanisms of Vaccination will bring together an interdisciplinary group of scientists in immunology, virology, systems biology and vaccinology, to address critical advances in these fields and their implications for vaccinology; The importance of the innate immune system in sensing vaccines and shaping the vaccine immunity; Modulating immune memory to vaccines with innate immunity; Novel approaches to understanding host-pathogen interactions; Deconstructing the mode of action of successful vaccines, vectors adjuvants with innate immunity; Constructing new vaccines and adjuvants with innate immunity; Application of systems biology to predicting vaccine efficacy, and discovering novel immune mechanisms of protection
Suggested reading: Vaccine Design: Innovative Approaches and Novel Strategies
Veterinary Vaccines
Category: Vaccines | Immunology
Veterinary Vaccines with a Focus on Bovine Mastitis
from John R. Middleton writing in Vaccine Design: Innovative Approaches and Novel Strategies
While novel approaches to vaccination against diseases of veterinary importance are being explored, currently marketed products, in general, employ old technology with the majority of products still being killed, modified live, or toxoid preparations. Due to the breadth of diseases encountered in veterinary medicine and the large number of vaccines marketed and under development, a recent review focuses on vaccines aimed at preventing bovine mastitis with a particular focus on Staphylococcus aureus, a bacterium that not only causes mastitis in cattle, but is a leading cause human infection. Vaccine developments for S. aureus in cattle will be compared with research aimed at preventing staphylococcal infection in humans. There are other available vaccines aimed at preventing bovine mastitis serving to illustrate that the goals of vaccination may differ depending on the type of infection being prevented.
Further reading: Vaccine Design: Innovative Approaches and Novel Strategies
from John R. Middleton writing in Vaccine Design: Innovative Approaches and Novel Strategies
While novel approaches to vaccination against diseases of veterinary importance are being explored, currently marketed products, in general, employ old technology with the majority of products still being killed, modified live, or toxoid preparations. Due to the breadth of diseases encountered in veterinary medicine and the large number of vaccines marketed and under development, a recent review focuses on vaccines aimed at preventing bovine mastitis with a particular focus on Staphylococcus aureus, a bacterium that not only causes mastitis in cattle, but is a leading cause human infection. Vaccine developments for S. aureus in cattle will be compared with research aimed at preventing staphylococcal infection in humans. There are other available vaccines aimed at preventing bovine mastitis serving to illustrate that the goals of vaccination may differ depending on the type of infection being prevented.
Further reading: Vaccine Design: Innovative Approaches and Novel Strategies
Group B Streptococcus Vaccine
Toward the Development of a Universal Vaccine Against Group B Streptococcus
from Roberta Cozzi, John L. Telford and Domenico Maione writing in Vaccine Design: Innovative Approaches and Novel Strategies
Group B Streptococcus (GBS) is one of the most common cause of life-threatening bacterial infections in infants and is also an emerging pathogen among adult humans, especially in the elderly, immunocompromised and diabetic adults. Capsular polysaccharide based vaccines of the most common serotypes present in the United States and Europe are in an advanced stage of development but they are not effective against serotypes present in other parts of the world. Many protein antigens have been studied for the discovery of an effective universal vaccine that could overcome serotype specificity. Thanks to reverse vaccinology and new technologies, a vaccine combination based on the pilus proteins has been discovered for the development of a universal GBS vaccine that is potentially capable of preventing all GBS infections.
Further reading: Vaccine Design: Innovative Approaches and Novel Strategies | Pili and Flagella: Current Research and Future Trends
from Roberta Cozzi, John L. Telford and Domenico Maione writing in Vaccine Design: Innovative Approaches and Novel Strategies
Group B Streptococcus (GBS) is one of the most common cause of life-threatening bacterial infections in infants and is also an emerging pathogen among adult humans, especially in the elderly, immunocompromised and diabetic adults. Capsular polysaccharide based vaccines of the most common serotypes present in the United States and Europe are in an advanced stage of development but they are not effective against serotypes present in other parts of the world. Many protein antigens have been studied for the discovery of an effective universal vaccine that could overcome serotype specificity. Thanks to reverse vaccinology and new technologies, a vaccine combination based on the pilus proteins has been discovered for the development of a universal GBS vaccine that is potentially capable of preventing all GBS infections.
Further reading: Vaccine Design: Innovative Approaches and Novel Strategies | Pili and Flagella: Current Research and Future Trends
Pseudomonas Vaccines
Category: Vaccines | Immunology
Vaccines to Combat Pseudomonas aeruginosa Infections in Immunocompromised Patients
from Jennifer M. Scarff and Joanna B. Goldberg writing in Vaccine Design: Innovative Approaches and Novel Strategies
Pseudomonas aeruginosa is an important opportunistic pathogen that causes an array of nosocomial infections, such as ventilator-associated pneumonia and infections in cancer patients. P. aeruginosa infections are difficult to treat with antibiotics, making the need for other therapeutic options, such as vaccination, critical. The main target antigen for vaccines has been the lipopolysaccharide (LPS) of P. aeruginosa and studies show that vaccination may be partially protective, but that a combination of vaccination with either antibiotic treatment or cell transfusion protocols typically works best. The efficacy of vaccination, particularly against LPS, has been investigated in human cancer patients. These patients were capable of mounting an immune response, but it was often short-lived or accompanied by severe side effects. An anti-Pseudomonas vaccine could be beneficial to aid in treatment of nosocomial infections caused by this bacterium, but would need optimization for better efficacy.
Further reading: Vaccine Design: Innovative Approaches and Novel Strategies | Pseudomonas: Genomics and Molecular Biology
from Jennifer M. Scarff and Joanna B. Goldberg writing in Vaccine Design: Innovative Approaches and Novel Strategies
Pseudomonas aeruginosa is an important opportunistic pathogen that causes an array of nosocomial infections, such as ventilator-associated pneumonia and infections in cancer patients. P. aeruginosa infections are difficult to treat with antibiotics, making the need for other therapeutic options, such as vaccination, critical. The main target antigen for vaccines has been the lipopolysaccharide (LPS) of P. aeruginosa and studies show that vaccination may be partially protective, but that a combination of vaccination with either antibiotic treatment or cell transfusion protocols typically works best. The efficacy of vaccination, particularly against LPS, has been investigated in human cancer patients. These patients were capable of mounting an immune response, but it was often short-lived or accompanied by severe side effects. An anti-Pseudomonas vaccine could be beneficial to aid in treatment of nosocomial infections caused by this bacterium, but would need optimization for better efficacy.
Further reading: Vaccine Design: Innovative Approaches and Novel Strategies | Pseudomonas: Genomics and Molecular Biology